FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF

The newly approved labeling for sacubitril/valsartan (Entresto) is simply for"chronic heart failure" but almost teasingly adds,"the benefits are most clearly evident" at below-normal LVEF.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news